A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
| 対象疾患 | Ulcerative Colitis, Ulcerative Colitis Chronic |
|---|---|
| 相 | 第3相 |
| スポンサー | Eli Lilly and Company |
| ステータス | 完了 |
| 参加者数 | 172 名 |
| 介入（薬剤） | Mirikizumab, Mirikizumab |
| 開始日 | 2023年5月17日 |
| 完了日 | 2024年8月9日 |
| 結果公開日 | 2025年9月30日 |
概要
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Change From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS)
| 300 mg Mirikizumab | -3.25 score on a scale |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
- GI Permeability Change in Response to Aquamin® — James Varani
- A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
- Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University